Dermatofibrosarcoma protuberans (DFSP) is an uncommon, low-grade sarcoma of fibroblast origin with an incidence rate of 0.8 cases per million persons each year. Although it rarely metastasizes, initial misdiagnosis, prolonged time to accurate diagnosis, and large tumor size at diagnosis are common. These updated 2007 guidelines include changes in recommendations for considering radiation therapy, as well as those regarding surgical margins in some patients.
For the most recent version of the guidelines, please visit NCCN.org
Vanderbilt-Ingram Cancer Center (VICC; vicc.org) is one of a select few NCI-designated centers in the Southeast and the only NCI-designated Comprehensive Cancer Center in Tennessee. Established under the leadership of Dr. Harold Moses in 1993, VICC brings together the cancer-related research, clinical care, education, prevention, and outreach activities at Vanderbilt University and Medical Center.
VICC's 250 faculty members in 7 research programs generate more than $135 million in research support from public and private sources. VICC focuses its efforts on high-impact basic and translational research and high quality multidisciplinary care, with particularly strong programs in phase I clinical trials, and lung, gastrointestinal, breast, head and neck, melanoma, pediatric, and hematologic malignancies. Its collaborative research initiatives include 3 Specialized Programs of Research Excellence, the Southern Community Cohort Study, and a U54 minority partnership with Meharry Medical College.
The center is led by interim director Jennifer A. Pietenpol, PhD (second photo on cover), Ingram Professor of Cancer Research, a biochemist with a research focus on tumor suppressor and cell cycle checkpoint signaling pathways. For more information about clinical trials, services, or second opinion consultation at VICC, call (800) 811-8480.